Roche Pharmaceutical Development and Sales Overview
PRED oncology development programs -2
Molecule
CD25 (RG6292)
Anti-GPRC5D (RG6234)
Indication
Solid tumors
Advanced and metastatic solid
tumors
Multiple myeloma
HLA-A2-WT1 x CD3 (RG6007)
AML
FAP-CD40 (RG6189)
Solid tumors
HLA-A2-MAGE-A4 x CD3 (RG6129)
Solid tumors
BRAFI (3) (RG6344)
Solid tumors
CD19xCD28 (RG6333)
R/R B cell non-Hodgkin's lymphoma
EGFRvlllxCD3 (RG6156)
Glioblastoma
Roche
Phase
# of patients
Status
CT Identifier
Oncology
|
110
FPI Q4 2019
NCT04158583
Part I: FPI Q1 2021
160
NCT04642365
Part II: FPI Q4 2021
FPI Q4 2020
240
NCT04557150
Data presented at EHA 2022
220
FPI Q4 2020
NCT04580121
280
FPI Q2 2021
|
260
FPI Q1 2022
292
FPI Q1 2022
FPI Q1 2022
~200
Combination study with glofitamab
|
~200
FPI Q2 2022
NCT04857138
NCT05129280
ISRCTN13713
551
NCT05219513
NCT05187624
131View entire presentation